» Articles » PMID: 34795663

Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma

Overview
Journal Front Immunol
Date 2021 Nov 19
PMID 34795663
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Interferon-gamma (IFN-γ) has a complex role in modulating the tumor microenvironment (TME) during renal cell carcinoma (RCC) development. To define the role of IFN-γ response genes in RCC progression, we characterized the differential gene expression, prognostic implications, and DNA variation profiles of selected IFN-γ response signatures, which exhibited a significant hazard ratio for the overall survival (OS) and progression-free survival (PFS) of papillary, chromophobia, and clear cell RCC (ccRCC) patients ( = 944). Prognostic nomograms were constructed to predict the outcomes for ccRCC patients, highlighting the prognostic implications of RANBP2-type and C3HC4-type zinc finger containing 1 (RBCK1). Interestingly, large-scale pan-cancer samples ( = 12,521) and three single-cell RNA datasets revealed that RBCK1 showed markedly differential expression between cancer and normal tissues and significantly correlated with tumor-infiltrating immune cells, tumor purity, and immune checkpoint molecules, such as PD-L1, CTLA-4, LAG-3, and TIGIT in pan-cancer samples. Notably, the TIDE score was significantly higher in the RBCK1 group compared with the RBCK1 group in both ccRCC and RCC cohorts. Besides, immunohistochemistry staining showed significantly elevated RBCK1 expression in tumors ( = 50) compared with kidney samples ( = 40) from a real-world cohort, Fudan University Shanghai Cancer Center (FUSCC, Shanghai). After RBCK1 expression was confirmed in ccRCC, we found a significantly decreased number of infiltrating CD4 T cells, CD4 FOXP3 Treg cells, M1 macrophages, and CD56 NK cells in the immune-cold RBCK1 group. In addition to the distinct heterogeneous immune microenvironment, the increased expression of RBCK1 predicted a prominently worse prognosis than the RBCK1 group for 232 ccRCC patients in the FUSCC proteomic cohort. Furthermore, after transfected with siRNA in human ccRCC cells, extraordinarily decreased cell proliferation, migration capacities, and prominently elevated apoptosis tumor cell proportion were found in the siRNA groups compared with the negative control group. In conclusion, this study identified IFN-γ response clusters, which might be used to improve the prognostic accuracy of immune contexture in the ccRCC microenvironment. Immune-cold RBCK1 patients have pro-tumorigenic immune infiltration and significantly worse outcomes than RBCK1 patients based on results from multi-omics to real-world data. Our discovery of novel independent prognostic indicators for RCC highlights the association between tumor alterations and immune phenotype.

Citing Articles

PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Zhu Z, Jin Y, Zhou J, Chen F, Chen M, Gao Z Mol Cancer. 2024; 23(1):146.

PMID: 39014460 PMC: 11251344. DOI: 10.1186/s12943-024-02059-y.


Development and Validation of a Prognostic Model based on 11 E3-related Genes for Colon Cancer Patients.

Jiang W, Dong J, Zhang W, Huang Z, Guo T, Zhang K Curr Pharm Des. 2024; 30(12):935-951.

PMID: 38898815 DOI: 10.2174/0113816128292398240306160051.


Inflammation and tumor microenvironment.

Niu T, Zhou F Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 48(12):1899-1913.

PMID: 38448384 PMC: 10930746. DOI: 10.11817/j.issn.1672-7347.2023.230231.


RBCK1 overexpression is associated with immune cell infiltration and poor prognosis in hepatocellular carcinoma.

Yu J, Liu T, Liu M, Jin H, Wei Z Aging (Albany NY). 2024; 16(1):538-549.

PMID: 38214606 PMC: 10817371. DOI: 10.18632/aging.205393.


CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers.

Gu Q, Zhou S, Chen C, Wang Z, Xu W, Zhang J Aging (Albany NY). 2023; 15(21):12369-12387.

PMID: 37944262 PMC: 10683612. DOI: 10.18632/aging.205184.


References
1.
Yuan Z, Yang H, Wei Y . Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. Int J Clin Exp Pathol. 2020; 12(1):123-132. PMC: 6944006. View

2.
Krenn M, Salzer E, Simonitsch-Klupp I, Rath J, Wagner M, Haack T . Mutations outside the N-terminal part of RBCK1 may cause polyglucosan body myopathy with immunological dysfunction: expanding the genotype-phenotype spectrum. J Neurol. 2017; 265(2):394-401. PMC: 5808061. DOI: 10.1007/s00415-017-8710-x. View

3.
Muntjewerff E, Meesters L, van den Bogaart G, Revelo N . Reverse Signaling by MHC-I Molecules in Immune and Non-Immune Cell Types. Front Immunol. 2021; 11:605958. PMC: 7770133. DOI: 10.3389/fimmu.2020.605958. View

4.
Xu W, Xu Y, Wang J, Wan F, Wang H, Cao D . Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging (Albany NY). 2019; 11(17):6999-7020. PMC: 6756904. DOI: 10.18632/aging.102233. View

5.
Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45(8):860-7. DOI: 10.1038/ng.2699. View